跳至主要内容
临床试验/TCTR20220329001
TCTR20220329001尚未招募2 期

Effects of cannabinoids for controlling spasticity in persons with chronic spinal cord injury: A double-blind crossover trial

The Government Pharmaceutical Organization of Thailand0 个研究点目标入组 16 人开始时间: 2022年3月29日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
16

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 99 Years(—)
性别
All

入选标准

  • Persons with traumatic spinal cord injury
  • Age between 20-65 years
  • Able to communicate in Thai
  • Onset of injury more than 1 year
  • Any level and severity of injury
  • Having intractable systemic spasticity (MAS > 2 despite receiving maximum tolerable oral antispastic drugs)

排除标准

  • Age < 20 years
  • Abnormal blood test
  • Severe Co-morbid disease
  • Pregnancy or breast feeding
  • History of psychotic disorder
  • First degree relative with schizophrenia
  • History of suicidal attempt or current suicidal idea
  • Currently on Carbamazepine, Phenytoin, Fluoxetine, Clobazam, Valproic acid
  • Currently use cannabinoids/cannabis
  • Positive urine cannabinoids screening

研究者

发起方
The Government Pharmaceutical Organization of Thailand

相似试验